Price
1,911.2
+0.58%52W Range
Market Cap
₹48,487.95 Cr
Traded: ₹37.03 Cr (0.08%) 0.0x
Free Float: ₹3,486.28 Cr (1.06% of FF traded)
Volume · 60D trend
1.94 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +14.0% | +13.0% | +13.0% | -- | -- | Stable |
| Return | +21.0% | +9.0% | +27.0% | +32.0% | -- | Accelerating |
| Profit | +30.0% | +1.0% | +37.0% | -- | +54.0% | Accelerating |
| Sales | +13.0% | +12.0% | +16.0% | -- | +11.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,788 | 2,388 | 2,392 | 2,556 | 2,309 | 2,247 | 2,245 | 2,355 | 2,093 | 2,033 | 2,053 | 2,034 | 1,585 | 1,512 | 1,546 | 1,601 |
| Expenses | 2,119 | 1,905 | 1,859 | 2,012 | 1,892 | 1,818 | 1,782 | 1,913 | 1,700 | 1,711 | 1,722 | 1,673 | 1,278 | 1,331 | 1,330 | 1,341 |
| Operating Profit | 670 | 484 | 533 | 545 | 416 | 429 | 463 | 441 | 393 | 322 | 331 | 361 | 308 | 181 | 216 | 260 |
| OPM % | 24.0% | 20.0% | 22.0% | 21.0% | 18.0% | 19.0% | 21.0% | 19.0% | 19.0% | 16.0% | 16.0% | 18.0% | 19.0% | 12.0% | 14.0% | 16.0% |
| Other Income | 25 | 48 | 38 | -30 | 33 | -179 | 20 | 26 | 21 | -118 | 91 | -1 | 45 | 36 | 31 | 36 |
| Interest | 12 | 20 | 18 | 20 | 19 | 22 | 17 | 23 | 24 | 29 | 33 | 44 | 31 | 18 | 11 | 9 |
| Depreciation | 111 | 107 | 108 | 103 | 100 | 100 | 98 | 100 | 99 | 98 | 100 | 90 | 69 | 70 | 67 | 64 |
| Profit Before Tax | 572 | 404 | 446 | 392 | 331 | 128 | 368 | 345 | 290 | 77 | 289 | 225 | 252 | 129 | 169 | 223 |
| Tax % | 26.0% | 24.0% | 18.0% | 28.0% | 29.0% | 49.0% | 25.0% | 29.0% | 31.0% | 96.0% | 23.0% | 39.0% | 34.0% | 37.0% | 32.0% | 35.0% |
| Net Profit | 424 | 307 | 364 | 281 | 233 | 64 | 276 | 246 | 199 | 1 | 221 | 136 | 164 | 78 | 110 | 146 |
| Exceptional Items | 0 | -46 | 18 | -58 | 0 | -205 | 0 | 0 | 0 | -137 | 68 | -39 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 15.8 | 11.8 | 12.9 | 11.1 | 9.2 | 2.7 | 9.8 | 9.1 | 7.6 | 2.4 | 7.1 | 5.7 | 6.4 | 3.0 | 4.3 | 5.7 |
| Sales Growth (YoY) | 20.7% | 6.3% | 6.5% | 8.5% | 10.3% | 10.5% | 9.3% | 15.8% | 32.0% | 34.5% | 32.8% | 27.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 16.8% | -0.2% | -6.4% | 10.7% | 2.8% | 0.1% | -4.7% | 12.5% | 3.0% | -1.0% | 0.9% | 28.3% | 4.8% | -2.2% | -3.4% | -- |
| OP Growth (YoY) | 61.1% | 12.8% | 15.1% | 23.6% | 5.9% | 33.2% | 39.9% | 22.2% | 27.6% | 77.9% | 53.2% | 38.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 38.4% | -9.2% | -2.2% | 31.0% | -3.0% | -7.3% | 5.0% | 12.2% | 22.0% | -2.7% | -8.3% | 17.2% | 70.2% | -16.2% | -16.9% | -- |
| Profit Growth (YoY) | 72.0% | 81.0% | 27.0% | 41.0% | 21.0% | 50.0% | 81.0% | 36.0% | 18.0% | 60.0% | 27.0% | 17.0% | 14.0% | -41.0% | -45.0% | -42.0% |
| EPS Growth (YoY) | 72.4% | 341.6% | 31.5% | 23.1% | 21.2% | 13.6% | 37.9% | 58.2% | 18.1% | -22.2% | 66.8% | 0.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 34.4% | -8.3% | 15.4% | 21.2% | 244.2% | -72.7% | 8.1% | 19.4% | 222.6% | -66.8% | 23.9% | -10.9% | 112.6% | -28.9% | -25.0% | -- |
| OP Margin | 24.0% | 20.3% | 22.3% | 21.3% | 18.0% | 19.1% | 20.6% | 18.7% | 18.8% | 15.8% | 16.1% | 17.8% | 19.4% | 12.0% | 14.0% | 16.2% |
| Net Margin | 15.2% | 12.9% | 15.2% | 11.0% | 10.1% | 2.9% | 12.3% | 10.4% | 9.5% | 0.1% | 10.8% | 6.7% | 10.3% | 5.2% | 7.1% | 9.1% |
| Material Cost % | 28.6% | 29.0% | 27.5% | 30.6% | 29.9% | 31.5% | 29.8% | 32.2% | 30.8% | 33.7% | 34.0% | 33.3% | 32.5% | 39.1% | 36.3% | 35.9% |
| Employee Cost % | 21.6% | 22.3% | 22.8% | 21.0% | 23.5% | 22.3% | 21.6% | 21.6% | 23.3% | 22.9% | 22.4% | 20.9% | 22.6% | 21.6% | 20.6% | 19.9% |
| P/S | 4.79 | 4.72 | 4.07 | 4.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 37.02 | 49.26 | 42.51 | 46.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.01 | 5.56 | 5.21 | 5.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Transcript of Conference Call
Audiolink for Conference Call held on 14.08.2026
Copy of Newspaper Publication
76th AGM - Voting Results and Scrutinizer Report
Proceedings of AGM
Standalone and Consolidated Unaudited Financial Results for Q1FY27
Standalone and Consolidated Unaudited Financial Results for Q1FY27
Intimation of web link to non-email cases
Copy of Newspaper Publication
Record Date for Dividend
76th Annual General Meeting of Ipca Laboratories Limited to be held on Thursday, 13th August, 2026
Business Responsibility and Sustainability Reporting (BRSR)
Annual Report 2025-26
The Company enclosed herewith certificate recived from RTA under reg 74 (5) D P Regulations for the quarter ended 30.06.2026.
Credit Rating
Copy of Newspaper Publication
Outcome of Board Meeting
Outcome of Board Meeting
Closure of Trading Window
Press Release
Eclsoed copy of newspapers
Revised Link for Q4FY26 Conference Call to be held today
Copy of Newspaper publications
Audio Link of the Conference Call held on 01.06.2026
Outcome of Board Meeting
Standalone and Consolidated Results Q4FY26
Re-appointment of Mr. Prashant Godha, as Executive Director
The Company has encloseing herewith Annual Secretarial Companice Report for the FY 2025-26.
Conference Call to discuss Q4FY26 Results
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
The Company has enclosing herewith certificate received from RTA under reg 74 (5) of DP Regulations for the quarter ended 31.03.2026.
Newspaper Notice issued by the Company regarding transfer of physical shares.
Closure of Trading Window
Transcript of Conference Call held on 16.02.2026
Audio Link for conference call held on 16.02.2026
Copy of Newspaper Publication
Commencement of commercial production at Company''s new manufacturing unit situated at Village Hingani, District - Wardha
Ipca Laboratories Ltd has informed BSE regarding "Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Concall Intimation to discuss Q3FY26 Results
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Re-lodgement of transfer request report - November 2025 and December 2025
Outcome of Board Meeting
Sale of 100% equity shares of wholly owned step-down subsidiary and updation of Registered Office Address
Updation in Registered Office Address
The Company has enclosed herewith RTA Certificate for the quarter ended 31.12.2025.
Closure of Trading Window
Inspection of Company''s Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Tarapur (Palghar-Maharashtra) by US FDA
Re-lodgement of transfer requests of physical shares Report - October 2025
Clarification sought on Volume Movement
Annual Reports
14Credit Ratings
6Concalls
31Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Apr 2023
30 Apr 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Jun 2021
30 Jun 2021Mar 2021
31 Mar 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Held by ETFs
23 ETFs hold ipcalab · sorted by weight
Held by Mutual Funds
92 schemes hold ipcalab · sorted by weight